Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Janssen Pharmaceuticals
Sort By
Newest First
Sign in
1 / 1
1 / 1
Digital Medicine
PhysIQ Announces Strategic Collaboration to Scale Digital Medicine
physIQ
PR-M04-21-019
Apr 20, 2021
Multiple Myeloma
Janssen Reports Positive Results for DARZALEX® in Multiple Myeloma
Emilie Branch
Pharma's Almanac
PAO-M12-19-NI-006
Dec 13, 2019
FDA Approval
Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Janssen Pharmaceutical Companies
PR-M10-19-NI-032-2050
Oct 22, 2019
Strategic Partnership
nference Enters into an R&D Data Science Strategic Partnership with Janssen
nference
PR-M06-19-NI-013
Jun 13, 2019
Drug Design
Janssen, Iktos Collaborate on In Silico Drug Design
Emilie Branch
Pharma's Almanac
PAO-M05-19-NI-022
May 21, 2019
FDA
Janssen Aims for Supplemental U.S. FDA Approval for INVOKANA®
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M04-19-NI-007
Apr 02, 2019
New Drug Application
Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
Janssen Pharmaceutical Companies
PR-M04-19-NI-008
Apr 02, 2019
HIV
Long-Acting Injectable HIV Treatment Regimen of Rilpivirine and Cabotegravir Demonstrated Comparable Safety and Efficacy to Daily Oral HIV Therapy
Johnson & Johnson
PR-M03-19-NI-033
Mar 12, 2019
Approval
Xarelto Gets Approval for Additional Indication
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M10-18-NI-019
Oct 22, 2018
